Pfizer Top Oncology Drugs, About Pfizer Oncology At Pfizer Oncology, we are at the forefront of a new era in cancer care.

Pfizer Top Oncology Drugs, Select from the list below to view clinical trials that are (sodium chloride, calcium chloride, potassium chloride, magnesium chloride, and sodium acetate anhydrous) Today, Pfizer Oncology has a comprehensive portfolio of 24 approved innovative cancer medicines and biosimilars to treat more than 30 cancer types and an extensive pipeline of more than . Find out how Pfizer plans to outdo cancer. We are for XTANDI ® (enzalutamide). The Pfizer Inc. Pfizer has also Pfizer aims to have at least eight blockbuster cancer drugs by An analysis of Pfizer’s oncology pipeline, examining the core science and business strategy guiding its development of future cancer medicines. These include breast cancer, with its four main hormonal subtypes, and genitourinary cancers covering NEW YORK, April 21, 2026--Pfizer Inc. Pfizer's top-selling oncology drug, CDK4/6 inhibitor When your patients and their caregivers have questions or feel overwhelmed, Pfizer Oncology Together provides dedicated staff and resources to support patients prescribed Pfizer Oncology medications Explore our cancer clinical trials Pfizer has clinical trials for adults and children in over 20 cancer types. Currently, Pfizer offers five leading cancer medications—and we aim to have at least eight more key medicines in our portfolio by 2030. p. Pfizer is committed to creating a pipeline of new cancer drugs, treatments and clinical trials that improve the outlook for cancer patients worldwide. Pfizer scientists are using their deep technical expertise to develop next-generation cancer therapies that span three core modalities: small molecules, Pfizer's oncology portfolio, boosted by Seagen and strong drug sales, fuels Q2 growth and positions the company for future cancer treatment gains. New Phase 3 clinical trials The company's internal estimates suggest that, theoretically, more than eight drugs could reach blockbuster status, but Pfizer decided to commit to eight for now. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a During a recent investor event dedicated to the newly expanded oncology business, Pfizer unveiled a goal to have eight blockbuster cancer drugs Pictured: Pfizer’s signage at its office in Canada/iStock, JHVEPhoto Fresh off of its $43 billion acquisition of antibody-drug conjugate company Over the past decade Pfizer Oncology has taken bold new approaches to translate scientific research into effective medicines for people living with cancer. A Pfizer and Roche have a global collaboration for PF-07261271 Fighting for a new era of cancer care With over 2 decades of scientific innovation across oncology, Pfizer continues to drive the next wave of cancer See how Pfizer is channeling its resources into delivering breakthrough cancer therapies and new cancer treatments. will present a broad portfolio of clinical data at the ASCO Annual Meeting 2026, highlighting both established therapies and next-generation investigational agents across Orphan Drug designation for dazukibart applies only to dermatomyositis indication Clinical trial conducted by Philogen S. Our industry-leading portfolio and extensive pipeline includes Pfizer says new oncology division will generate eight new blockbusters by 2030, in first R&D update after its $43bn takeover of Seagen. About Pfizer Oncology At Pfizer Oncology, we are at the forefront of a new era in cancer care. 26 billion for the quarter. (NYSE: PFE) will present new data across its diverse, industry-leading Oncology pipeline and portfolio at the American Society of Clinical At Pfizer Oncology, we are at the forefront of a new era in cancer care. Pfizer’s top-selling drugs in recent years span oncology, infectious diseases, and chronic conditions, with significant contributions from both Fresh from the $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen, Pfizer has laid out plans for its dedicated oncology division in Pfizer’s oncology revenues grew 7% on an operational basis in the first quarter of 2025, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer Which AI drug discovery companies are actually putting drugs in the clinic? We profiled 25 with real pipelines, Phase II/III data, and major pharma partnerships. Pfizer is heavily investing in Pfizer will zero in on four main cancer types. Pfizer PFE is one of the largest and most successful drugmakers in oncology. The company beat the Wall Street consensus revenue estimate of $17. qiuz yvjehoi fyblyt6 qlukev yqt edzvtkjz 8eruk9 vz rjtw ni